Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 8Active not recruiting 2Withdrawn 1Completed 1Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Dermatologic 1

Conditions

Uveal Melanoma 1Select Advanced Solid Tumors 1Melanoma 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × tebentafusp × Clear all
NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT05315258 2025-07-17

TebeMRD

University of Oxford

Phase 2 Active not recruiting
850 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡